Neuester, zuletzt geles. Beitrag
Antworten | Hot-Stocks-Forum
Übersicht
... 12 13 14 1 2 3 4 ...

Grosse Chance WKN 931506

Beiträge: 342
Zugriffe: 24.168 / Heute: 2
GENESIS PHARM. kein aktueller Kurs verfügbar
 
Grosse Chance WKN 931506 plusquamperfekt
plusquamperf.:

Grosse Chance WKN 931506

3
04.04.07 09:33
#1
Der Kurs müsste bei uns bei über 0,115 stehen, wir handeln aber zu 0,103 in Frankfurt  
Warum ? Weil einige gestern gierig und überstürzt in den Wert rein sind in der Hoffnung auf schnelle 100% (nach den News) - heut schmeissen sie unter pari (grins)
Das kann man ausnutzen - der Hype kommt meiner Meinung nach erst noch !

Time & Sales  
          §Price Size     Exch Time
t   0.155 5000     OBB 16:01:38
  0.1539 5000     OBB 15:58:29
  0.154 5000     OBB 15:58:28
  0.1539 7250     OBB 15:58:24
  0.1539 25000     OBB 15:57:09
  0.154 25000     OBB 15:57:07
  0.1539 10000     OBB 15:46:32
  0.15 18000     OBB 15:05:08
  0.15 10000     OBB 15:05:02
  0.1539 1000     OBB 14:52:49
  0.1539 2400     OBB 14:41:05
  0.15 10000     OBB 14:36:41
  0.15 6000     OBB 14:33:08
  0.15 1000     OBB 14:31:30
  0.15 4000     OBB 14:30:02
  0.15 1000     OBB 14:29:58
  0.1539 1000     OBB 14:28:07
  0.1539 5600     OBB 14:25:03
  0.1539 5000     OBB 14:08:33
  0.1539 20000     OBB 14:07:20
  0.1539 5000     OBB 14:04:48
  0.15 30000     OBB 13:41:20
  0.15 5000     OBB 13:38:35
  0.15 25000     OBB 13:38:33
  0.15 20000     OBB 13:36:31
  0.15 5730     OBB 13:23:22
316 Beiträge ausgeblendet.
Seite: Übersicht ... 12 13 14 1 2 3 4 ...


Grosse Chance WKN 931506 _bbb_
_bbb_:

8k

 
13.06.08 10:57
Form 8-K for GENESIS PHARMACEUTICALS ENTERPRISES, INC.


--------------------------------------------------

12-Jun-2008

Change in Directors or Principal Officers, Financial St



Item 5.02. Departure of Directors or Certain Officers; Election of Directors, Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.
On June 9, 2008, the Board of Directors of Genesis Pharmaceuticals Enterprises, Inc. (the "Company") by unanimous written consent approved the hiring of Elsa Sung as the full-time Chief Financial Officer of the Company effective June 10, 2008.

Ms. Sung, age 34, has served as Chief Financial Officer of the Company since October 2007. Prior to June 2008, she was also Vice President of CFO Oncall, Inc. Prior to joining CFO Oncall, Inc., Ms. Sung was an Audit Manager at Sherb & Co., Boca Raton, Florida, responsible for managing, monitoring, as well as performing audits for domestic and international clients. Before joining Sherb & Co., Ms. Sung was a Senior Internal Auditor at Applica Consumer Products, Inc., a U.S. public traded company. Prior to this, Ms. Sung was with Ernst & Young, LLP in West Palm Beach, Florida as a Senior Auditor in the Assurance and Advisory Business Service Group. Ms. Sung is a licensed CPA in the State of Georgia and a member of the American Institute of Certified Public Accountants. She received her Master of Business Administration and Bachelor's Degree, graduated "Cum Laude", in Accounting from Florida Atlantic University. She also holds a Bachelor's Degree in Sociology from National Chengchi University in Taipei, Taiwan.

The Company and Ms. Sung executed an employment agreement effective as of June 10, 2008 (the "Employment Agreement"). In accordance with the terms of the Employment Agreement, Ms. Sung will receive an annual base salary of $120,000 and will be entitled to receive performance bonuses of (i) $18,000 if the Company is successfully listed or quoted on the New York Stock Exchange, the American Stock Exchange, the NASDAQ Select Market, the NASDAQ Global Market or the NASDAQ Capital Market; (ii) $8,000 if the Company meets its 2008 Guaranteed EBT; and (iii) $20,000 if the Company meets its 2009 Guaranteed EBT. In addition, Ms. Sung will be granted 300,000 options in accordance with the vesting and pricing schedule set forth in the Employment Agreement.

The foregoing description of the Employment Agreement is merely a summary, is not intended to be complete and is qualified in its entirety by reference to the full text of the Employment Agreement. The Employment Agreement is filed as Exhibit 10.1 to this Form 8-K, and the full text of such exhibit is incorporated herein by reference.

Ms. Sung has no family relationships with any of the executive officers or directors of the Company. There have been no transactions in the past two years to which the Company or any of its subsidiaries was or is to be a party, in which Mr. Sung had, or will have, a direct or indirect material interest.





Item 9.01 Financial Statements and Exhibits.

Exhibit No.    Description

10.1          Employment Agreement, effective as of June 10, 2008 by and between
             Genesis Pharmaceuticals Enterprises, Inc. and Elsa Sung


Grosse Chance WKN 931506 sunwin
sunwin:

Hier die Übersetzung auf google deutsch

 
13.06.08 12:58
Veränderung bei den Direktoren oder Principal Officers-, Finanz-St



Posten 5,02. Abfahrt of Directors oder bestimmte Officers; Wahl der Direktoren, die Bestellung bestimmter Officers; Ausgleichsvereinbarung bestimmter Officers.
Am 9. Juni 2008, das Board of Directors der Genesis Pharma Enterprises, Inc. (das "Unternehmen") durch einstimmigen schriftlichen Zustimmung genehmigt die Einstellung von Elsa Sung als die Vollzeit-Chief Financial Officer des Unternehmens wirksam 10. Juni 2008.

Frau Sung, Alter 34, diente als Chief Financial Officer des Unternehmens seit Oktober 2007. Vor Juni 2008, sie war auch Vice President des CFO Oncall, Inc. Vor seinem Eintritt bei CFO Oncall, Inc., Frau Sung wurde ein Audit Manager bei Sherb & Co., Boca Raton, Florida, verantwortlich für die Verwaltung, Überwachung, wie ebenso wie die Durchführung Audits für nationale und internationale Kunden. Vor seinem Wechsel zu Sherb & Co., Frau Sung war ein Senior Internal Auditor bei Applica Consumer Products, Inc., eine US-amerikanische Öffentlichkeit gehandelten Unternehmen. Davor war Frau Sung wurde mit Ernst & Young LLP in West Palm Beach, Florida als Senior Auditor bei der Assurance and Advisory Business Service Group. Frau Sung ist ein lizenzierter CPA im US-Bundesstaat Georgia und Mitglied des American Institute of Certified Public Accountants. Sie erhielt ihren Master of Business Administration und Bachelor-Abschluss, Diplom "cum laude", im Rechnungswesen aus Florida Atlantic University. Sie ist außerdem Inhaber eines Bachelor's Degree in Soziologie von National Chengchi University in Taipei, Taiwan.

Die Gesellschaft und Frau Sung ausgeführt einen Arbeitsvertrag Vereinbarung mit Wirkung zum 10. Juni 2008 (der "Beschäftigungs-Abkommen"). In Übereinstimmung mit den Bestimmungen des Abkommens Beschäftigung, Frau Sung erhalten ein jährliches Grundgehalt von 120000 $ und wird Anspruch auf Leistung Boni von (i) $ 18000, wenn das Unternehmen erfolgreich ist bzw. notiert an der New York Stock Exchange, der American Stock Exchange, der NASDAQ wählen, der NASDAQ Global Market oder den NASDAQ Capital Market, (ii) $ 8000, wenn das Unternehmen seinen EBT 2008 garantiert, und (iii) $ 20000, wenn das Unternehmen seinen EBT 2009 garantiert. Darüber hinaus, Frau Sung wird gewährt 300000 Optionen im Einklang mit der Unverfallbarkeit und Preisgestaltung festgelegten Zeitplan in den beschäftigungspolitischen Abkommens.

Die vorstehende Beschreibung der Beschäftigung Abkommens ist lediglich eine Zusammenfassung, erhebt keinen Anspruch auf Vollständigkeit und qualifiziert ist in seiner Gesamtheit durch einen Verweis auf den Volltext der Beschäftigung Abkommens. Die Beschäftigung Abkommens eingereicht wird als 10,1 Ausstellung zu diesem Formular 8-K, und der vollständige Wortlaut dieser Ausstellung ist hierin durch Bezugnahme.

Frau Sung hat keine familiären Beziehungen mit einem der leitenden Beamten oder Direktoren des Unternehmens. Es wurden keine Transaktionen in den vergangenen zwei Jahren, an denen die Gesellschaft oder einer ihrer Tochtergesellschaften wurde oder wird eine Partei, in der Herr Sung hatten oder haben wird, eine direkte oder indirekte materielle Interesse.
Grosse Chance WKN 931506 toni800
toni800:

Es bleibt spannend!

 
13.06.08 14:49

Man kann nur Vermutungen aufstellen, wie es weiter geht.

Hoffentlich wirds gut.

 

MfG

Grosse Chance WKN 931506 toni800
toni800:

Es...

 
16.06.08 19:04

Es scheint wirklich so zu sein, dass sich die Aktie bei 20 / 21 US Cents stabilisiert.

 

 

Grosse Chance WKN 931506 _bbb_
_bbb_:

Video

 
19.06.08 14:19
video] WallSt.net's '3 Minute Press Show' Features Executive Interviews and Highlights Recent Press for the Following: DAI, OPX
Date : 06/19/2008 @ 7:00AM
Source : PR Newswire
<< Back

[video] WallSt.net's '3 Minute Press Show' Features Executive Interviews and Highlights Recent Press for the Following: DAI, OPX





NEW YORK, June 19 /PRNewswire/ -- WallSt.net's 3-Minute Press Show is a daily video program hosted by WallSt.net reporter, Tracee Tolentino.

Shows air Monday through Friday on: tv.wallst.net/.

WallSt.net's 3-Minute Press Show features in-depth interviews with public company executives on their company and most recent press releases. The show is designed to provide viewers with insight into a company's most recent press release, and its impact on the company's growth.

The following executives were interviewed on today's show:

Han Tjan, Head of North American Corporate Communications for Daimler AG (NYSE:DAI) (www.daimler.com/). To view this clip in its entirety, visit:

www.tv.wallst.net/r/3-minute-press/mktmaker/113/539

David McWilliams, President and CEO of Opexa Therapeutics, Inc. (NASDAQ:OPXA) (www.opexatherapeutics.com/). To view this clip in its entirety, visit:

www.tv.wallst.net/r/3-minute-press/kazman/113/537

Declan Byrne, Chief Marketing Officer of Airspan Networks, Inc. (NASDAQ:AIRN) (www.airspan.com/). To view this clip in its entirety, visit:

www.tv.wallst.net/r/3-minute-press/emceecooper/113/540

Chaim Levinson, Director of Investor Relations for BrainStorm Cell Therapeutics, Inc. (OTC:BCLI) (BULLETIN BOARD: BCLI) (www.brainstorm-cell.com/). To view this clip in its entirety, visit:

www.tv.wallst.net/r/3-minute-press/aquaman/113/541

Elsa Sung, Chief Financial Officer of Genesis Pharmaceuticals Enterprises, Inc. (OTC:GTEC) (BULLETIN BOARD: GTEC) (www.genesis-china.net/). To view this clip in its entirety, visit:

www.tv.wallst.net/r/3-minute-press/aquaman/113/542

Jeffrey Ross, Director of Finance for Newport Digital Technologies, Inc., a wholly-owned subsidiary of International Food Products Group, Inc. (OTC:IFDG) (BULLETIN BOARD: IFDG) (www.newportdt.com/). To view this clip in its entirety, visit:

www.tv.wallst.net/r/3-minute-press/wsdave/113/538

About WallStreet Direct, Inc.


WallStreet Direct, Inc. a wholly-owned subsidiary of Financial Media Group, Inc. (OTC:FNGPOTC:-OTC:News) (BULLETIN BOARD: FNGP - News) , owns and operates WallSt.net (www.wallst.net/), a leading source of up-to-the-minute business news, comprehensive financial tools and original multimedia content for the investment community. In addition to WallSt.net, WallStreet Direct owns and operates WallStRadio (radio.wallst.net/) an online hub for business podcasts from well-known business news personalities and publishers, and WallStTV (tv.wallst.net/), a hub for business and finance video content. We have received four million restricted shares of IFDG from International Food Products Group, Inc. for media and advertising services. We have received two hundred eighty dollars from BrainStorm Cell Therapeutics, Inc. for press release dissemination services provided in 2007. To read our full disclaimer, and for a complete list of our advertisers, and advertising relationships, visit www.wallst.net/disclaimer/disclaimer.php.

Contact WallSt.net 800-4-WALLST

DATASOURCE: WallStreet Direct, Inc.; Opexa Therapeutics, Inc.; BrainStorm
Grosse Chance WKN 931506 0815ax
0815ax:

_bbb_: gibt es neue Meldungen

 
24.06.08 18:19
(u.a. aus deinem ihub-thread zu GTEC ) ???

  --ax--
*amM - keine Kaufempfehlung
...wer Rechtschreibfehler findet - kann sie behalten !!!

             RWE - 3.LIGA wir sind dabei
Grosse Chance WKN 931506 _bbb_
_bbb_:

@ax

 
24.06.08 19:40
Nee mir ist nix neues bekannt...meiner Meinung nach guter Preis zum nachlegen...leider keine Kohle ! :)
Grosse Chance WKN 931506 0815ax
0815ax:

dito!

 
24.06.08 19:48
*amM - keine Kaufempfehlung
...wer Rechtschreibfehler findet - kann sie behalten !!!

             RWE - 3.LIGA wir sind dabei
Grosse Chance WKN 931506 duffyduck
duffyduck:

wie gehts hier weiter?

 
27.06.08 09:10
keinerlei meldung...
Grosse Chance WKN 931506 toni800
toni800:

der Kurs

 
30.06.08 18:20

Klebt bei 21 US Cents.

 

So wirds wahrscheinlich auch eine ganze Weile bleiben?!

 

MfG 

Grosse Chance WKN 931506 _bbb_
_bbb_:

:)

 
30.06.08 18:24
Zumindest stabiler Kurs, runter gehts nimmer mehr IMO !
Also wenn ich kohle hätte würde ich gern nachlegen...
Grosse Chance WKN 931506 0815ax
0815ax:

_bbb_ - Hurra, wir leben noch! (Umsatz zieht an)

 
02.07.08 19:25
USA: bis dato 82T$
Grosse Chance WKN 931506 172745
*amM - keine Kaufempfehlung
...wer Rechtschreibfehler findet - kann sie behalten !!!

             RWE - 3.LIGA wir sind dabei

25.07.08 Eröffnunsspiel (LIVE-mdr) 3.Liga  RWE-SGD
Grosse Chance WKN 931506 toni800
toni800:

ja in der Tat!

 
03.07.08 18:13

Die Börsenstimmung ist relativ mies!

Aber Genesis hält gut die Stellung zwischen 20-22 US Cents !

 

Mfg 

Grosse Chance WKN 931506 0815ax
0815ax:

Frage in die Diskussionsrunde -

 
06.07.08 19:42
...in wie weit kann/wird sich dies auf GTEC auswirken (Werbung / Gewinne ...)
Grosse Chance WKN 931506 173347
*amM - keine Kaufempfehlung
...wer Rechtschreibfehler findet - kann sie behalten !!!
                       
25.07.08 Eröffnunsspiel 3.Liga: RWE-SGD
DFB-Pokal 1.Runde: RWE-Bayern München
Grosse Chance WKN 931506 toni800
toni800:

Hallo 0815ax ,

 
07.07.08 17:47

Wie meinst du das?

Ist GTEC denn vor Ort da oder als Verpfleger dort? 

 

MfG 

Grosse Chance WKN 931506 _bbb_
_bbb_:

NEWS !

 
15.07.08 17:13
Genesis Pharmaceuticals Announces SFDA Approval for Radix Isatidis Dispersible Tablets
Date : 07/15/2008 @ 11:04AM
Source : PR Newswire
<< Back

Genesis Pharmaceuticals Announces SFDA Approval for Radix Isatidis Dispersible Tablets





LAIYANG, China, July 15 /Xinhua-PRNewswire-FirstCall/ -- Genesis Pharmaceuticals Enterprises, Inc. (OTC:GTEC) (BULLETIN BOARD: GTEC) ("Genesis" or the "Company"), a leading pharmaceutical company in the People's Republic of China, today announced that the Company received approval from the Chinese State Food and Drug Administration ("SFDA") to start producing and distributing Radix Isatidis Dispersible Tablets.

Radix Isatidis is an herbal-based traditional Chinese medicine used to cure viral influenza. Radix Isatidis is very popular in China because people there believe it has fewer side affects than western medicines. Most Radix Isatidis products are in powder form, which has to be dissolved in hot water. Genesis will be the only company in China to manufacture Radix Isatidis in dispersible tablet form. Radix Isatidis Dispersible Tablets will be more convenient to take, easier to absorb and are more stable than Radix Isatidis products in powder form.

Radix Isatidis Dispersible Tablets will be sold over the counter in pharmacies, a rapidly growing distribution channel for drugs in China. The Company will start distributing Radix Isatidis Dispersible Tablets within three months, and will make this medicine widely available to customers throughout China.

Annual sales of Radix Isatidis in China are estimated to be over US$1.43 billion. The Company estimates that its sales of Radix Isatidis Dispersible Tablets in fiscal year 2009 ending June 30, 2009 will be approximately US$4.2 million and an estimated US$10 million in fiscal year 2010.

Genesis has all of manufacturing equipment needed to produce Radix Isatidis Dispersible Tablets, and has concluded its marketing research and planning for this new product. The Company estimates that its first year working capital and marketing expenses will be approximately US$1.0 million.

"We are pleased to receive approval from the SFDA to produce and distribute Radix Isatidis Dispersible Tablets," said Mr. Cao Wubo, Chairman and CEO of Genesis Pharmaceuticals Enterprises. "We will distribute this new drug through our existing nationwide marketing and distribution network, and believe it will quickly become popular among a wide range of customers, from young to old people."

About Genesis Pharmaceuticals Enterprises, Inc.

Genesis Pharmaceuticals Enterprises, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Northeast China in an Economic Development Zone in Laiyang City, Shandong province. Genesis is a major pharmaceutical company in China producing tablets, capsules, and granules for both western and Chinese herbal- based medical drugs.

Safe Harbor Statement

Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to introduce, manufacture and distribute new drugs. Actual results may differ materially from anticipated or predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

For more information, please contact:

Genesis Pharmaceuticals Enterprises, Inc.

Ms. Elsa Sung, CFO Tel: +1-954-727-8436 Email: Web: www.genesis-china.net/

CCG Elite Investor Relations, Inc.

Mr. Crocker Coulson, President Tel: +1-646-213-1915 Email: Web: www.ccgelite.com/

DATASOURCE: Genesis Pharmaceuticals Enterprises, Inc.


CONTACT: Ms. Elsa Sung, CFO of Genesis Pharmaceuticals Enterprises, Inc.,

+1-954-727-8436, or ; Mr. Crocker Coulson, President of

CCG Elite Investor Relations, Inc., +1-646-213-1915, or



Web site: www.genesis-china.net/

www.ccgelite.com/
Grosse Chance WKN 931506 0815ax
0815ax:

...was lange dauert, wird endlich gut...

 
15.07.08 17:55
good news!
*amM - keine Kaufempfehlung
...wer Rechtschreibfehler findet - kann sie behalten !!!
                       
25.07.08 Eröffnunsspiel 3.Liga: RWE-SGD
DFB-Pokal 1.Runde: RWE-Bayern München
Grosse Chance WKN 931506 _bbb_
_bbb_:

@ax

 
15.07.08 18:00
Ja genau...darauf haben wir gewartet ! :)
Grosse Chance WKN 931506 duffyduck
duffyduck:

wie gut ist die meldung wirklich

 
15.07.08 21:28
??
Grosse Chance WKN 931506 toni800
toni800:

hallo duffy,

 
15.07.08 22:02

diese meldung ist sehr gut!

einfach lesen :-)

 

gruß 

Grosse Chance WKN 931506 duffyduck
duffyduck:

.

 
15.07.08 22:12
der kurs springt aber nicht so an.

Grosse Chance WKN 931506 _bbb_
_bbb_:

NEWS!

 
23.07.08 17:37
Genesis Pharmaceuticals Announces New Board Member and Forms Committees





LAIYANG, China, July 23 /Xinhua-PRNewswire-FirstCall/ -- Genesis Pharmaceuticals Enterprises, Inc. (OTC:GTEC) (BULLETIN BOARD: GTEC) ("Genesis" or the "Company"), a leading pharmaceutical company in the People's Republic of China, held a Board of Directors meeting on July 18, 2008 at which a new Board member was appointed to serve on the Board of Directors of the Company, and an Audit Committee and a Compensation Committee were formed.

Mr. Michael Marks was appointed to the Company's Board of Directors on July 18, 2008. Since 2007, he has served as an independent director of China Housing & Land Development, Inc., a property developer in China. In 2006, Mr. Marks became President of Middle Kingdom Alliance Corp., a publicly traded Special Purpose Acquisition Corporation active in China. In 2003, Mr. Marks founded the China practice of Sonnenblick Goldman, a real estate investment bank, and served as its Managing Director in China until 2007. In 2001, he founded B2Globe, providing technology solutions to international internet businesses in Asia. In 1999, he co-founded Metro Corporate Training in Shanghai to offer training and management development, and was its Chief Executive Officer until 2001. During his nine-year tenure in China, Mr. Marks has had a role as advisor, banker or principal in over $2 billion of transactions. From 1998 to 1999, Mr. Marks worked as a management consultant with Horwath Asia Pacific in Australia and China. From 1995 to 1998, Mr. Marks worked in the audit, corporate finance and advisory divisions of PricewaterhouseCoopers in South Africa. Mr. Marks received a Bachelor of Commerce (Honors) in 1994 and Masters of Commerce in 1997 from the University of the Witwatersrand in Johannesburg, South Africa. In 1998, he graduated with a Bachelor of Arts (Psychology) degree from the University of South Africa. In 1997, Mr. Marks became a Chartered Accountant in South Africa, and a Fellow of the Association of International Accountants in the United Kingdom in 1999. He speaks fluent Mandarin, French and English.

The Board of Directors accepted the resignations of Mr. Zhang Yihua and Mr. Rodrigo Arboleda. The resignations of Mr. Zhang and Mr. Arboleda from the Company's Board of Directors were not the result of any disagreements with the Company on any matter relating to the Company's operations, policies or practices.

"I look forward to working with Genesis," stated Michael Marks. "Having participated in the growth of a number of companies in China, I know that Genesis is a company with a tremendous future. I am excited to be a part of its development."

The Board of Directors authorized and approved creation of an Audit Committee that will oversee matters relating to the Company's financial reporting. Qualifying as an "audit committee financial expert" in compliance with applicable SEC and current stock exchange rules and regulations, Michael Marks was appointed as the Chairman of the Audit Committee. Each member of the Audit Committee is "independent" as defined in Section 10A of the Securities Exchange Act of 1934.

The Board of Directors also authorized and approved creation of a Compensation Committee that will, among other things, make recommendations to the Board of Directors concerning salaries and incentive compensation for the Company's officers. Feng Xiaowei was appointed as the Chairman of the Compensation Committee. Each member of the Compensation Committee is "independent" as defined in Section 10A of the Securities Exchange Act of 1934.

"We are pleased to welcome Michael Marks to serve as a member of our Board of Directors. We believe that he will make an immediate and valuable contribution to the work of our Board," said Mr. Cao Wubo, Chairman and CEO of Genesis Pharmaceuticals Enterprises. "At its last meeting, our Board of Directors created an Audit Committee and Compensation Committee composed of independent Board members. We believe that the establishment of these committees will help to assure investors that Genesis is fully committed to the highest possible standards of corporate governance."

About Genesis Pharmaceuticals Enterprises, Inc.

Genesis Pharmaceuticals Enterprises, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Northeast China in an Economic Development Zone in Laiyang City, Shandong province. Genesis is a major pharmaceutical company in China producing tablets, capsules, and granules for both western and Chinese herbal- based medical drugs.

Safe Harbor Statement

Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to introduce, manufacture and distribute new drugs. Actual results may differ materially from anticipated or predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

For more information, please contact:

Genesis Pharmaceuticals Enterprises, Inc.

Ms. Elsa Sung, CFO Tel: +1-954-727-8436 Email: Web: www.genesis-china.net/

CCG Investor Relations, Inc.

Mr. Crocker Coulson, President Tel: +1-646-213-1915 Email: Web: www.ccgir.com/

DATASOURCE: Genesis Pharmaceuticals Enterprises, Inc.


CONTACT: Ms. Elsa Sung, CFO of Genesis Pharmaceuticals Enterprises, Inc.,

+1-954-727-8436, or ; Mr. Crocker Coulson, President of

CCG Elite Investor Relations, Inc., +1-646-213-1915, or



Web site: www.genesis-china.net/

www.ccgelite.com/

Grosse Chance WKN 931506 0815ax
0815ax:

...wichtige Daten im August

 
03.08.08 18:14

Thursday August 14th Forms 13F and 10-Q for filers with quarters ending June 30, 2008(45 days after period end)

Friday August 15th Notification of Late Filing (NT 10-Q) for Form 10-Q/10QSB, if 10-Q/10QSB is not filed on time(Due on the business day after the 10-Q due date.)

Wednesday August 20th Extended deadline for filing a Form 10-Q/10QSB after filing a NT 10-Q (Due 5 calendar days after original filing due date)

*amM - keine Kaufempfehlung
...wer Rechtschreibfehler findet - kann sie behalten !!!
                       
25.07.08 Eröffnunsspiel 3.Liga: RWE-SGD  0:1
DFB-Pokal 1.Runde: RWE-Bayern München
Grosse Chance WKN 931506 toni800
toni800:

Hallo zusammen!

 
12.08.08 19:55

Seid ihr alle noch investiert?

 

Mein anlagehorizont ist mehrer jahre.

 

sollte eigentlich nicht schief gehen.

 

Gruß

Tonci 

Grosse Chance WKN 931506 _bbb_

FYI ! Hier gehts zum aktuellen Thread...

 

Seite: Übersicht ... 12 13 14 1 2 3 4 ...

Hot-Stocks-Forum - Gesamtforum - Antwort einfügen - zum ersten Beitrag springen

Neueste Beiträge aus dem GENESIS PHARMACEUTICALS ENTE Forum

  
Wertung Antworten Thema Verfasser letzter Verfasser letzter Beitrag
24 2.508 Sunwin ( SUWN ) explodiert ! gameznman toi-toi-toi 30.09.19 17:51
6 770 $$ D E T O N A T I O N $$ Calibra21 paris03 26.06.12 16:45
3 341 Grosse Chance WKN 931506 plusquamperfekt _bbb_ 02.05.10 14:39
  1 telefonkonferenz pat24 Infodienste 17.03.09 11:06
  19 Löschung 0815ax 0815ax 05.09.08 22:48

--button_text--